Aktis Oncology, Inc. (AKTS)

NASDAQ · Pharmaceuticals & Biotech · Pharmaceutical Preparations

Price
$22.11
Day
+3.17%
Market cap
$1.22B

Close 2026-09-22.

The company

Our pipeline We are leveraging our proprietary miniprotein radioconjugate platform to discover and develop a deep pipeline of targeted radiopharmaceutical programs to address unmet needs in prevalent solid tumors. Our most advanced program, [ 225 Ac]Ac-AKY-1189, is targeting Nectin-4 expressing solid tumors, including locally advanced or metastatic UC, breast cancer, NSCLC, colorectal cancer and cervical cancer. Our second most advanced program, [ 225 Ac]Ac-AKY-2519, is targeting B7-H3 expressing solid tumors, such as prostate, lung and breast cancers. Beyond [ 225 Ac]Ac-AKY-1189 and [ 225 Ac]Ac-AKY-2519, we have a robust discovery pipeline of several unpartnered miniprotein radioconjugate programs in the discovery phase that focus on clinically-validated targets. Our learnings from the optimization of [ 225 Ac]Ac-AKY-1189 are being applied to benefit the development of [ 225 Ac]Ac-AKY-2519 and these subsequent programs. We retain exclusive, worldwide development and commercialization rights to all our current product candidates and discovery programs. We also have a discovery collaboration with Eli Lilly and Company, or Eli Lilly, to generate novel anticancer radiopharmaceuticals against targets beyond the scope of our unpartnered pipeline programs.

From Item 1: Our pipeline.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Recent filings